NEW YORK, Oct. 05, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

RADNOR, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024. CONTA ...

SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom’s top executives with violations of the Se ...

Legal Investigation - Kuehn Law PLLC is investigating potential breaches of fiduciary duties by DexCom Inc officers and directors [1] - A federal securities lawsuit alleges DexCom insiders misrepresented or failed to disclose material information regarding 2024 revenue expectations [1] Financial Impact - DexCom reduced its full fiscal year 2024 revenue guidance on July 25 2024 [1] - The company attributed the lowered guidance to the execution of several key strategic initiatives that did not meet their high standards [1] - DexCom's stock price fell to $64 00 representing a 40 66% decline following the announcement [1] Shareholder Involvement - Long-term DexCom stockholders are encouraged to contact Kuehn Law for a free consultation regarding the case [2] - Shareholder participation is emphasized as important for maintaining the integrity and fairness of financial markets [3]

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

Core Viewpoint - DexCom, Inc. has faced significant stock price decline following the announcement of its second quarter financial results for fiscal 2024 and a reduction in revenue guidance for the full fiscal year 2024, attributed to unmet strategic initiatives [2][3] Group 1: Financial Performance - On July 25, 2024, DexCom announced its second quarter financial results and lowered its revenue guidance for the full fiscal year 2024 [2] - The company's stock price dropped from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in one day [2] Group 2: Legal Action - Shareholders who purchased shares of DexCom during the class period from January 8, 2024, to July 25, 2024, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment [1][2] - The deadline for shareholders to register for the class action is October 21, 2024, and there is no cost or obligation to participate [3] Group 3: Company Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [4]

DexCom, Inc. (DXCM) is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust second-quarter 2024 performance, along with a series of favorable coverage decisions, is expected to contribute further. However, risks related to stiff competition persist.This Zacks Rank #3 (Hold) company’s shares have lost 46.8% year to date against the industry’s 9.9% growth. The S&P 500 Index has increased 21.1% in the same time frame.DXCM, a renowned medical device company and provide ...

DexCom Stock Performance and Market Position - DexCom stock is down by about 53% from its peak in April, despite starting the year with healthy gains [1] - The company markets one of the world's most popular continuous glucose monitors (CGM), which transmit data to smartphones or Apple Watches [1] - DexCom's stock fell by about 40% in July after management lowered its sales guidance, with Q3 sales growth expected to be only 1% to 3% year over year [2] - Full-year revenue expectations were revised down to $4 billion to $4.05 billion, from a previous range of $4.2 billion to $4.35 billion [2] Competitive Landscape - Abbott Laboratories, DexCom's lead competitor, did not issue a similar sales slowdown warning, raising investor concerns [2] - Abbott's FreeStyle Libre CGM sales grew 18.4% year over year in Q2 to $1.6 billion, about 60% more than DexCom's CGM revenue in the same period [3] - Medtronic, another major player, received FDA approval for its first disposable all-in-one CGM in August, intensifying competition [6] - Abbott and Medtronic announced a collaboration combining Abbott's CGM technology with Medtronic's insulin delivery system, potentially strengthening Abbott's market position [7] Market Opportunity and Product Innovation - DexCom's addressable market is large, with 29.4 million diagnosed diabetic adults in the U.S. and an estimated 8.7 million undiagnosed cases [4] - Approximately 38% of U.S. adults have prediabetes, creating additional demand for glucose monitoring [4] - DexCom launched Stelo, an over-the-counter CGM for non-insulin users, in August to tap into the growing market of health-conscious individuals [4] Challenges and Risks - DexCom's forward price-to-earnings ratio of 39.8 is high, suggesting the stock could fall further if the Q3 sales slowdown persists [5] - Eli Lilly's tirzepatide study showed a 94% reduction in the risk of progression to type 2 diabetes, potentially shrinking DexCom's addressable market [6] - DexCom's stock is not considered a bargain at its current valuation, and investors may need to wait for a return to previous growth rates [8]

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. due to significant stock price decline following the company's lowered sales guidance and operational issues [1][3] Financial Performance - On July 25, 2024, DexCom lowered its full year 2024 sales guidance to between $4 billion and $4.05 billion, a reduction of approximately $300 million from the previous guidance of $4.20 billion to $4.35 billion [2] - The company reported a "new patient shortfall" of 70,000 patients attributed to a "sales force disruption" and loss of market share in the Durable Medical Equipment channel [2] Stock Market Reaction - Following the announcement of the lowered guidance, DexCom's stock price fell by $43.85 per share, over 40%, closing at $64 per share on July 26, 2024 [3] Allegations in Lawsuit - The lawsuit alleges that during the class period, DexCom provided overly positive statements while concealing material adverse facts about its salesforce capabilities, leading to artificially inflated stock prices [3]

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...